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Background: Persistent suboptimal glycemic control is invariably associated with onset and 
progression of acute and chronic diabetic complications in diabetic patients. In Uganda, studies 
documenting the magnitude and predictors of suboptimal glycemic control in adult ambulatory 
diabetic patients are limited. This study aimed at determining the frequency and predictors of 
suboptimal glycemic control in adult diabetic patients attending three urban outpatient diabetic 
clinics in Uganda.
Methods: In this hospital-based cross-sectional study, eligible ambulatory adult diabetic patients 
attending outpatient diabetic clinics of three urban hospitals were consecutively enrolled over 
11 months. Suboptimal glycemic control was defined as glycated hemoglobin (HbA
1c
) level 
≥7%. Multivariable analysis was applied to determine the predictors.
Results: The mean age of the study participants was 52.2±14.4 years, and the majority of them 
were females (283, 66.9%). The median (interquartile range) HbA
1c
 level was 9% (6.8%–12.4%). 
Suboptimal glycemic control was noted in 311 study participants, accounting for 73.52% of 
the participants. HbA
1c
 levels of 7%–8%, 8.1%–9.9%, and ≥10% were noted in 56 (13.24%), 
76 (17.97%), and 179 (42.32%) study participants, respectively. The documented predictors of 
suboptimal glycemic control were metformin monotherapy (odds ratio: 0.36, 95% confidence 
interval: 0.21–0.63, p<0.005) and insulin therapy (odds ratio: 2.41, 95% confidence interval: 
1.41–4.12, p=0.001).
Conclusion: Suboptimal glycemic control was highly prevalent in this study population with 
an association to metformin monotherapy and insulin therapy. Strategies aimed at improving 
glycemic control in diabetes care in Uganda should be enhanced.
Keywords: suboptimal glycemic control, frequency, predictors, Africa, Uganda
Introduction
Acute diabetic complications such as diabetic ketoacidosis and chronic micro- and 
macrovascular diabetic complications and their associated adverse outcomes are 
intimately related to suboptimal glycemic control in clinical practice. Each 1% reduc-
tion in the mean glycated hemoglobin (HbA
1c
) has been shown to be associated with 
reduction in risk of 21% for deaths related to diabetes, 14% for myocardial infarction, 
and 37% for microvascular complications.1 Despite this unequivocal clinical evidence 
that underscores the value of optimal glycemic control among diabetic patients, studies 
from sub-Saharan Africa and other regions of the world still document that majority 
of the patients in clinical care do not attain the recommended glycemic targets.2–4 This 
ultimately translates to increased risk of onset and progression of the fatal diabetic 
complications, hence increasing morbidity and mortality.
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Due to the economic growth and ensuing rapid urban-
ization, there is a demonstrable growing trend of diabetes 
mellitus (DM) and other noncommunicable diseases  in 
Uganda. Several published community-based cross-sectional 
studies performed in different regions of rural and semi-urban 
Uganda have reported different prevalence of DM ranging 
from 0.4% to 9%.5–8 The disparity in the reported prevalence 
could probably be explained by the differences in the study 
diagnostic methods. A recently concluded representative 
national survey on the burden of noncommunicable diseases 
in Uganda using the standardized World Health Organiza-
tion’s stepwise approach reported a low prevalence of DM 
of 1.4%, which is also lower than the International Diabetes 
Federation 2014 estimate of 4.4%.9,10
Despite this growing trend of DM in Uganda, studies 
assessing the levels of glycemic control and related factors 
among adult diabetic patients are limited. The objective of 
this study was to determine the frequency of suboptimal 
glycemic control and its related factors among adult dia-
betic patients attending outpatients’ diabetic clinics at three 
urban hospitals in Kampala, the capital city of Uganda. This 
information obtained will be integral in influencing evidence-
based policy formulation and implementation in the national 
and institutional diabetes management programs.
Study methods
Study design, setting, and selection criteria
This was a cross-sectional study performed between Septem-
ber 2014 and July 2015 in three outpatient diabetic clinics of 
Mulago National Referral and Teaching Hospital, a public 
hospital where health services are offered at no charge, and at 
Mengo Hospital and Our Lady of Consolata Hospital Kisubi, 
which are not-for-profit, faith-based hospitals where health 
services are offered at subsided fees. All these hospitals man-
age an adult diabetes clinic at least once weekly.
At each center, patients aged ≥18 years with a diagnosis 
of diabetes confirmed by a general practitioner or physician 
using fasting blood glucose levels, an oral glucose tolerance 
test, HbA
1c
, or random blood sugar level in the presence of 
symptoms of diabetes and having been receiving care for at 
least a minimum of 6 months were enrolled consecutively 
until the desired sample size was attained. All eligible patients 
offered written informed consent prior to being enrolled into 
the study.
Data collection
Using a pretested questionnaire, information about the study 
participants’ sociodemographic characteristics, preexisting 
medical conditions (coexisting hypertension and HIV), type 
of diabetes, age at diagnosis of DM, duration since diagnosis, 
and drug history were collected. All participants underwent 
standard anthropometric measurements to calculate the 
body mass index (BMI), and blood pressure (BP) was also 
measured. A fasting venous blood sample was obtained from 
each study participant after consent for determination of the 
HbA
1c
 levels and to perform a fasting lipid profile. The analy-
sis was done at each center using a full automated COBAS® 
integra 400 (Roche Diagnostics GmbH, Indianapolis, IN, 
USA) machine.
Statistical analysis
Data were entered into Microsoft Excel database, and 
Stata software (College Station, TX, USA), version 12.1 
was used for all statistical analysis. Patient characteristics 
were reported as frequency and percentage for categorical 
variables, mean and standard deviation  for the normally 
distributed continuous variables, and median and interquartile 
range (IQR) for continuous variables that were not normally 
distributed.
The 2015 American Diabetes Association (ADA) 
guidelines of standards of care of diabetes care were used 
to define suboptimal glycemic control as HbA
1c
 levels 
≥7%. Other components of optimal diabetes care were 
also defined as follows: optimal BP <140/90 mmHg, 
optimal low-density lipoprotein cholesterol ≤2.6 mmol/L, 
high-density lipoprotein cholesterol ≥1 mmol/L for men 
and ≥1.3 mmol/L for women, triglyceride ≤1.7 mmol/L, 
and total cholesterol concentrations ≤5 mmol/L.11 Propor-
tions of participants with HbA
1c
 levels of <7%, 7%–8%, 
8.1%–9.9%, and ≥10% were analyzed. In addition, we also 
analyzed the proportion of participants with: 1) optimal BP, 
glycemic, and lipid control; 2) optimal BP and glycemic 
control; 3) optimal BP and lipid control; and 4) optimal 
lipid and glycemic control.
To determine associations between the different sociode-
mographic, clinical, and laboratory factors and suboptimal 
glycemic control, bivariate analyses using χ2 test were 
performed. Multivariate analysis was then performed to 
identify the independent predictors. A p-value of <0.05 and 
confidence intervals (CIs) not including 1 were considered 
to be statistically significant.
Ethics approval
This study was approved by the ethics review board of Mak-
erere University College of Health Sciences, Mengo Hospital, 
and Our Lady of Consolata Hospital Kisubi.
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Results
Sociodemographic and clinical 
characteristics of the study participants
The mean age of the study participants was 52.2±14.4 years, 
with majority being females (283, 66.9%). Most of the study 
participants were educated to a primary or lower level of 
education (165, 39%) and were urban dwellers (288, 67.9%). 
A low prevalence of smoking (2.35%) was reported among 
the study participants.
Type 2 DM diagnosed using clinical criterion was the most 
common type of DM in this study population, accounting for 
86.87% of the cases. Hypertension as a comorbidity and a 
family history of DM were also frequently seen, accounting 
for 68.87% and 62.26% of the participants, respectively. This 
study population had a relatively short duration of diabetes 
(median duration [IQR]: 4.5 [2–10] years) and a young age 
at diagnosis (median duration [IQR]: 47 [37–55] years). With 
regard to glycemic therapy, majority were on a combination 
of oral hypoglycemic therapy and conservative approach 
(236, 56.66%). Insulin therapy either as monotherapy or 
in combination with metformin was used in 188 (44.34%) 
participants (Table 1).
Glycemic, BP, and lipid control among the 
study participants
Of the study participants enrolled, results of 423 participants 
were complete, and so these were used to analyze the extent 
of glycemic, BP, and lipid control. The median HbA
1c
 was 9 
(6.8–12.4) %. Only 112 (26.48%) of the study participants 
had optimal glycemic control as defined by the 2015 ADA 
guidelines of diabetes management (ie, <7%). Majority of 
the participants had suboptimal glycemic control, defined as 
HbA
1c
 ≥7% (311, 73.52%).
Considering other components of diabetes care, a very 
small proportion of the study participants had optimal gly-
cemic, lipid, and BP control collectively (9, 2.1%). Optimal 
glycemic and BP control, glycemic and lipid control, and lipid 
Table 1 Sociodemographic, clinical, and laboratory characteristics 
of the study participants
Variable N (%)
Age in years, median (IQR) 53 (43.5–62)
Gender, n (%)
Male 140 (33.02)
Female 284 (66.98)
Education level, n (%)
None 38 (8.96)
Primary 165 (38.92)
Secondary 141 (33.25)
Tertiary 79 (18.63)
Occupation, n (%)
Employed 212 (50)
Unemployed 212 (50)
Marital status, n (%)
Married 259 (61.08)
Cohabiting 10 (2.36)
Single 47 (11.08)
Divorced 41 (9.67)
Widow/widowed 67 (15.80)
Place of residence
Rural 136 (32.08)
Urban 288 (67.92)
Study site
Government 199 (46.82)
Private 226 (53.18)
Smoking
Yes 10 (2.35)
No 415 (97.65)
Variable N (%)
Known HT
Yes 292 (68.87)
No 132 (31.13)
HIV coexistent
Yes 17 (4.00)
No 408 (96.00)
FH-DM
Yes 264 (62.26)
No 160 (37.74)
Type of DM
Type 1 DM 55 (13.13)
Type 2 DM 364 (86.87)
Drug history
Diet alone 3 (0.71)
Metformin alone 79 (18.59)
Met + SU 127 (29.88)
Met + SU + TZD 16 (3.76)
Met + Incretins 8 (1.88)
Insulin alone/+Met 188 (44.34)
Statins 89 (20.94)
Variable Median (IQR), N=425
Age at diagnosis, years 47 (37–55)
Duration with DM, years 4.5 (2–10)
BMI, kg/m2 27 (23–30.6)
HbA1c (%) 9 (6.8–12.4)
LDLC, mmol/L 2.9 (2.3–3.84)
HDLC, mmol/L 1.19 (0.9–1.42)
TC, mmol/L 4.82 (4.1–5.71)
TGL, mmol/L 1.6 (1.23–2.2)
SBP, mmHg 139 (124–155)
DBP, mmHg 80 (73–91)
Note: Copyright ©2017. Dove Medical Press. Reproduced from Lumu W, Kampiire L, 
Akabwai GP, Kiggundu DS, Kibirige D. Statin therapy reduces the likelihood of 
suboptimal blood pressure control among Ugandan adult diabetic patients. Ther Clin 
Risk Manag. In press 2017.19
Abbreviations: IQR, interquartile range; DM, diabetes mellitus; HT, hypertension; 
FH, family history; SU, sulfonylureas; Met, metformin; Pio, pioglitazone; BMI, body 
mass index; HbA1c, glycated hemoglobin; LDLC, low-density lipoprotein cholesterol; 
HDLC, high-density lipoprotein cholesterol; TC, total cholesterol; TGL, triglycerides; 
SBP, systolic blood pressure; DBP, diastolic blood pressure; TZD, thiazolidinediones. 
(Continued)
Table 1 (Continued) 
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plus BP control were documented in only 13.9%, 3.6%, and 
6.4% of the participants,  respectively (Table 2).
Sociodemographic, clinical, and laboratory 
characteristics of the study participants 
at bivariate analysis
At bivariate analysis, metformin monotherapy (p<0.005), use 
of insulin therapy either as monotherapy or in combination 
with metformin (p<0.005), and systolic BP (p=0.01) were 
statistically significant. There was a trend toward signifi-
cance for age of the study participants (p=0.052). Table 3 
Table 2 Extent of glycemic, BP, and lipid control among the 
study participants (n=423)
HbA1c (%) N (%)
<7 112 (26.48)
7–8 56 (13.24)
8.1–9.9 76 (17.97)
≥10 179 (42.32)
All L (LDLC, HDLC, TC, TGL collectively), BP, HbA1c 
normal 
9 (2.1)
HbA1c-BP normal 59 (13.9)
HbA1c-L normal 15 (3.6)
L-BP normal 27 (6.4)
Abbreviations: L, lipid profile; HbA1c, glycated hemoglobin; BP, blood pressure; 
LDLC, low-density lipoprotein cholesterol; HDLC, high-density lipoprotein 
cholesterol; TC, total cholesterol; TGL, triglycerides.
Table 3 Bivariate analysis of sociodemographic and clinical 
characteristics associated with suboptimal glycemic control
Characteristic HbA1c ≥7%, 
n (%)
HbA1c <7%, 
n (%)
OR (95% CI) p-value
Age, years
≤40 30 (20.69) 82 (29.50) 0.62 (0.39–1.01) 0.052
>40 115 (79.31) 196 (73.52)
Gender
Male 41 (29.50) 98 (0.50) 0.79 (0.51–1.25) 0.325
Female 71 (25.00) 213 (75.00)
Type of hospital
Government 56 (28.14) 143 (71.86) 0.85 (0.55–1.31) 0.466
Private 56 (25) 168 (75)
Place of residence
Rural 28 (20.74) 107 (79.26) 1.57 (0.96–2.57) 0.067
Urban 84 (29.17) 204 (70.83)
Smoking
Smoker 3 (30.00) 7 (73.00) 0.84 (0.21–3.30) 0.799
Nonsmoker 109 (26. 39) 304 (73.61)
Coexisting HT
Yes 78 (26.71) 214 (73.29) 0.96 (0.60–1.54) 0.870
No 34 (25.95) 97 (74.05)
DM type
Type 1 DM 13 (23.64) 42 (76.36) 1.21 (0.62–2.35) 0.571
Type 2 DM 99 (27.27) 264 (72.73)
Family history of DM
Yes 70 (26.52) 194 (73.48) 0.99 (0.64–1.55) 0.982
Characteristic HbA1c ≥7%, 
n (%)
HbA1c <7%, 
n (%)
OR (95% CI) p-value
No 42 (26.42) 117 (73.58)
HIV comorbidity
Yes 5 (29.41) 12 (70.59) 0.86 (0.30–2.50) 0.780
No 107 (26.35) 299 (73.65)
Median years with DM
≤10 89 (27.55) 234 (72.45) 1.27(0.75–2.16) 0.368
>10 23 (23.00) 77 (77.00)
BP, mmHg
≤140/90 55 (23.81) 176 (76.19) 0.74 (0.48–1.14) 0.173
>140/90 57 (29.69) 135 (70.31)
BMI, kg/m2
≤25 44 (26.83) 120 (73.17) 1 1
25.1–29 23 (21.90) 82 (78.10) 1.31 (0.73-2.33) 0.363
≥30 42 (30.43) 96 (69.57) 0.84 (0.51-1.38) 0.489
Glucose-lowering therapy, n (%)
Metformin  
alone
41 (52.56) 37 (47.44) 0.23 (0.14–0.40) <0.005
Met + SU 34 (26.77) 93 (73.23) 0.98 (0.61–1.57) 0.929
Incretins + Met 1 (12.50) 7 (87.50) 2.56 (0.31–21.10) 0.366
Met + SU + 
TZD
6 (37.50) 10 (62.50) 0.59 (0.21–1.66) 1.309
Insulin alone/+ 
Met
27 (14.36) 161 (85.64) 3.38 (2.04–5.59) <0.005
On statin therapy, 
n (%)
26 (29.21) 63 (70.79) 0.84 (0.500–1.41) 0.511
LDLC, mmol/L
≤2.6 45 (29.22) 109 (70.78) 1.26 (0.80–1.97) 0.32
>2.6 64 (24.71) 195 (75.29)
HDLC, mmol/L
<1 33 (26.61) 76 (26.39) 1.01 (0.62–1.63) 0.962
≥1 76 (26. 39) 212 (73.61)
TC, mmol/L
≤5 64 (27.95) 165 (72.05) 1.19 (0.76–1.85) 0.443
>5 45 (24.59) 138 (75.41)
TGL, mmol/L
≤1.7 65 (27.78) 169 (72.22) 1.18 (0.76–1.84) 0.466
>1.7 44 (24.58) 135 (75.42)
Non-HDLC, mmol/L
<3.4 49 (29.52) 117 (70.48) 1.29 (0.83–2.02) 0.248
≥3.4 60 (24.39) 186 (75.61)
TC/HDLC ratio
<4.5 68 (29.06) 166 (70.94) 1.37(0.87–2.15) 0.170
≥4.5 41 (23.03) 137 (76.97)
SBP, mmHg
<140 45 (21.03) 169 (78.97) 0.56 (0.36–0.88) 0.01
≥140 67 (32.06) 142 (67.94)
DBP, mmHg
<90 72 (26.37) 201 (73.63) 0.99 (0.63–1.55) 0.948
≥90 40 (26.67) 110 (73.33)
Abbreviations: OR, odds ratio; CI, confidence interval; DM, diabetes mellitus; 
BP, blood pressure; HT, hypertension; FH, family history; SU, sulfonylureas; Met, 
metformin; BMI, body mass index; HbA1c, glycated hemoglobin; LDLC, low-density 
lipoprotein cholesterol; HDLC, high-density lipoprotein cholesterol; TC, total 
cholesterol; TGL, triglycerides; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; TZD, thiazolidinediones.
(Continued)
Table 3 (Continued) 
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summarizes the sociodemographic, clinical, and laboratory 
characteristics of the study participants in association with 
suboptimal glycemic control at bivariable analysis.
Independent predictors of suboptimal 
glycemic control at multivariate analysis
The documented predictors of suboptimal glycemic con-
trol were only glucose-lowering therapies, ie, metformin 
 monotherapy (odds ratio [OR]: 0.36, 95% CI: 0.21–0.63, 
p<0.005) and insulin therapy (OR: 2.41, 95% CI: 1.41–4.12, 
p=0.001). Place of residence of the study participants was 
not statistically significant after multivariate analysis (OR: 
0.64, 95% CI: 0.38–1.07, p=0.089) (Table 4).
Discussion
This study documents a high prevalence of suboptimal 
glycemic control among this ambulatory Ugandan adult 
diabetic population. The identified independent predictors 
of suboptimal glycemic control were only glucose-lowering 
therapies, ie, metformin monotherapy and insulin therapy.
Comparable high frequencies of suboptimal glycemic con-
trol have been reported in several studies performed in Africa 
and other developing countries. In the largest sub-Saharan Afri-
can study assessing the quality of diabetes care in 2,352 type 
2 DM patients, the mean HbA
1c
 was 8.2%±2.4%, with 71% of 
the patients having suboptimal HbA
1c
, defined as levels >6.5%.2 
Other similar studies in Ethiopia, South Africa, and Uganda 
have documented frequencies of suboptimal glycemic control 
to be between 64.7% and 79.2%.12–15 In another large study 
of 1,179 diabetic patients from Eastern Europe, Asia, Latin 
America, and Africa called the International Diabetes Mellitus 
Practice Study (IDMPS), suboptimal glycemic control defined 
as HbA
1c
 greater than 7% was noted in 75% of the patients.16
The probable reasons to explain these high proportions of 
patients with suboptimal glycemic control in our developing 
countries, as demonstrated in some of the studies, include 
lack of access to HbA
1c
 monitoring, inequitable access to 
diabetes medication, delay, and fear to initiate and optimize 
insulin therapy among health care workers, low levels of 
patient education, and, generally, knowledge gaps in diabetes 
management among the health care workers.2,14–16
Independent predictors of suboptimal 
glycemic control
The two identified independent predictors were metformin 
monotherapy and insulin therapy. Metformin monotherapy 
was noted to have a protective effect against suboptimal 
glycemic control in our study. Similarly in the IDMPS, 
among patients on oral glucose-lowering therapy, the use 
of fewer oral therapies was associated with attainment of 
optimal glycemic goals in all the regions studied.16 Fewer 
medications in clinical practice generally tend to improve 
patient drug adherence and compliance, hence resulting in 
better treatment outcomes. Metformin monotherapy in clini-
cal practice might reflect mild severity or early disease with 
easy attainment of glycemic goals.
Insulin therapy was noted to increase the odds of subopti-
mal glycemic control. This has also been reported in similar 
studies from Ethiopia and Brazil.12,17 However, poor glycemic 
control cannot be directly attributed to insulin therapy per se. 
In diabetes care, there is an observed clinical inertia, which 
can be defined as the failure to initiate, establish appropriate 
targets, and optimize treatment so as to achieve treatment 
goals with regard to insulin therapy.18 This could be due to 
the physician’s lack of knowledge and experience with insulin 
use and the patient’s fear of insulin-induced hypoglycemia 
and weight gain. There is also hesitancy among patients to 
accept insulin treatment due to fear of pain of injections, cost, 
hypoglycemia, and weight gain. Insulin use is, thus, reserved 
for only patients with severe disease or for patients later in the 
disease course and for those that have failed to reach glycemic 
goals despite very high doses of oral glucose-lowering drugs.
Study limitations
Due to the small sample size and cross-sectional nature of the 
study as well as its performance in an urban hospital setting, 
we cannot establish temporal relationships and also generalize 
to the entire adult diabetic population seeking care in Uganda.
Conclusion and recommendations
Suboptimal glycemic control is a highly prevalent finding 
among adult diabetic patients affecting about seven in ten 
patients. Metformin monotherapy and insulin therapy either 
in monotherapy or in combination with metformin were 
observed to be independent predictors of suboptimal glyce-
mic control. There is an imperative need to improve optimal 
glycemic management in adult diabetic patients.
Table 4 Independent predictors of suboptimal glycemic control 
on multivariable analysis
Variable Unadjusted Adjusted analysis
OR (95% CI) p-Value OR (95% CI) p-Value
Place of  
residence
1.57 (0.96–2.57) 0.067 0.64 (0.38–1.07) 0.089
Metformin  
monotherapy
0.23 (0.14–0.40) 0.000 0.36 (0.21–0.63) <0.005
Insulin therapya 3.38 (2.04–5.59) 0.000 2.41 (1.41–4.12) 0.001
Note: aEither in monotherapy or in combination with metformin.
Abbreviations: OR, odds ratio; CI, confidence interval.
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